A Mass Balance Study Following Subcutaneous Administration of [14C]-ITI-1284 to Healthy Male Subjects

Inclusion Criteria: * Healthy male subjects between 30 and 55 years of age (inclusive); * BMI between18.0 and 32.0 kg/m2, inclusive, at screening, and a minimum body weight of 50 kg at screening; * Willing to be confined to the clinical research unit for the duration of the inpatient period of the study. Exclusion Criteria: * Radiation exposure, including that from the present study, excluding background radiation but including diagnostic X-rays and other medical exposure, exceeding 5 mSev in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker shall participate in the study; * Subjects who have been enrolled in a 14C-labeled product study in the 10 months prior to dosing with study drug on Day 1; * Any clinical condition or procedure that may affect the absorption, distribution, biotransformation, or excretion of ITI-1284. Subjects with a history of appendectomy and/or abdominal wall hernia repair are eligible for study participation provided surgery was performed ≥1 year ago; * Acute diarrhea or constipation in the 7 days before Day 1. If screening occurs \> 7 days before Day 1, this criterion will be determined on Day 1; * Clinically significant abnormal findings in vital sign assessments, supine SBP \> 140 mmHg or \< 90 mmHg, or supine DBP \>90 mmHg or \< 50 mmHg or supine pulse rate \> 100 bpm or \< 45 bpm at Screening; * History of psychiatric condition that in the Investigator's opinion may be detrimental to participation in the study.